drugset
drugset / Trial / NCT00568776

ELND005 in Patients With Mild to Moderate Alzheimer's Disease

NCT00568776 ↗

Phase 2 Completed 353 enrolled OPKO Health, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).

Timeline

Start
2007-12
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator SCYLLITOL Small molecule 250 mg Oral
Comparator SCYLLITOL Small molecule 1000 mg Oral
Comparator SCYLLITOL Small molecule 2000 mg Oral

Indications

Alzheimer disease